| |
|
|
|
|
|
DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board
|
|
Vancouver, BC, May 28, 2019--DelMar Pharmaceuticals (Nasdaq: DMPI), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced the appointments of three additional world-class neuro-oncologists to its Scientific Advisory Board (SAB).
|
|
|
|
|
|
|
|
DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center's IRB for Protocol Expansion
|
|
Vancouver, BC, April 10, 2019--DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI), a Vancouver-based biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced this week that the University of Texas MD Anderson Cancer Center's (MDACC) Institutional Review Board (IRB) has approved a trial protocol amendment to expand DelMar's ongoing Phase 2 clinical trial of VAL-083 in patients with MGMT-unmethylated glioblastoma (GBM).
|
|
|
|
|
|
|
|
|
|
DelMar Pharmaceuticals Receives Nasdaq Listing Extension
|
|
Vancouver, BC, February 12, 2019--DelMar Pharmaceuticals, Inc.(Nasdaq: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, announced that it has received a listing extension from the Nasdaq Hearings Panel.
|
|
|
|
|
|
|
|
DelMar Announces Further Validation of the Mechanism of Action of VAL-083
|
|
Vancouver, BC, October 25, 2018--DelMar Pharmaceuticals, Inc.(NASDAQ: DMPI), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced the publication of a peer-reviewed scientific paper on the mechanism of action for VAL-083, the Company's product candidate, in Cell Death and Disease by Nature Publishing Group.
|
|
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
